Northwestern Medicine is offering a free virtual CME series to help you stay connected and meet your CME requirements. Join Northwestern faculty as they address the latest advances in the field in respect to diagnosis, treatment and management of neurodegenerative disease.
Wednesday, June 14, 2022, from 5:30 PM – 7:30 PM (CST)
Zoom Webinar
Program Objectives
After attending this educational activity, participants should be able to:
- Discuss and apply diagnostic criteria for Parkinson’s disease.
- Identify and appropriately recommend available disease modifying treatment in PD.
- Identify and appropriately recommend treatment options for early and advanced PD.
- Explain how to diagnosis and manage ataxia.
- Review new surgical options for management of movement disorders.
- Demonstrate when to consult specialist for patients with Huntington’s disease.
- Consult allied healthcare professionals appropriately in the management of patients with Parkinson’s and other movement disorders.
- Summarize current state-of-the-field in the diagnosis and experimental therapeutics of dementias in the context of movement disorders.
Speakers:
Course Director
Audience
The content of this program is appropriate for neurologists, nurses, nurse practitioners, physical therapists, physician assistants and genetic counselors.
Accreditation Statement
The Northwestern University Feinberg School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
The Northwestern University Feinberg School of Medicine designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Information
Speakers:
Danielle N. Larson, MD, states she received consulting fees from Acadia Pharmaceuticals but this relationship has ended. Puneet Opal, MD, PhD, states he receives royalties from UpToDate, receives fees as an associated editor for the American Neurological Association and receives funding for clinical trials with Biohaven Pharmaceuticals. Allan D. Wu, MD, has nothing to disclose.
Course Directors, Planning Committee and CME Program Manager:
Puneet Opal, MD, PhD, states he receives royalties from UpToDate, receives fees as an associated editor for the American Neurological Association and receives funding for clinical trials with Biohaven Pharmaceuticals. Dimitri Krainc, MD, has nothing to disclose. Sarah Baggs has nothing to disclose.
FSM’s CME Leadership and Staff have nothing to disclose:
Clara J. Schroedl, MD, Medical Director of CME, Sheryl Corey, Director of CME, Allison McCollum, Senior Program Coordinator, Katie Daley, Senior Program Coordinator, Michael Rooney, Senior Program Coordinator, and Rhea Alexis Banks, Administrative Assistant 2.
All of the relevant financial relationships listed for these individuals have been mitigated.
